The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Cancer Policy

FDA halts public release of Complete Response Letters, following citizen petition

Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds

CMS proposes end-of-life counseling provision, echoing ACA “death panels” controversy

FDA proposes rule to hold foreign tobacco companies to U.S. standards

AACR urges OMB to retract proposed rule on federally funded research

CDC updates ACIP charter

Clinical Roundup

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

HIF-2α inhibitor casdatifan yields 35% response rate in kidney cancer, phase I study finds

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

Should lowest-risk prostate cancer still be called “cancer”? UCLA-led study suggests changing the name could save lives

Equal access to cancer care removes race as predictor of survival, VA analysis finds

In The Clinic

Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note
One woman’s pregnancy shows how this distinction matters

FreeTrials & Tribulations
FreeTrials & Tribulations
Trials & Tribulations
Trials & Tribulations

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account